Overcoming Cancer Drug Resistance with Hydralazine
Author Information
Author(s): Segura-Pacheco Blanca, Perez-Cardenas Enrique, Taja-Chayeb Lucia, Chavez-Blanco Alma, Revilla-Vazquez Alma, Benitez-Bribiesca Luis, Duenas-Gonzalez Alfonso
Primary Institution: Unidad de Investigación Biomédica en Cáncer, Instituto de Investigaciones Biomédicas, Universidad Nacional Autonóma de Mexico
Hypothesis
Can DNA hypermethylation contribute to chemotherapy resistance in cancer cells, and can it be reversed by demethylating agents?
Conclusion
DNA hypermethylation contributes to the development of multidrug resistance in cancer cells, and hydralazine can reverse this resistance.
Supporting Evidence
- MCF-7/Adr cells showed increased DNA hypermethylation compared to wild-type MCF-7 cells.
- Hydralazine treatment restored adriamycin sensitivity in MCF-7/Adr cells.
- DNA methyltransferase activity was higher in resistant cells, indicating a role in drug resistance.
- Antisense targeting of dnmt genes reduced methylation and increased drug sensitivity.
Takeaway
Some cancer cells become resistant to treatment because of changes in their DNA. A medicine called hydralazine can help make these cells sensitive to treatment again.
Methodology
MCF-7 cells were treated with adriamycin to induce resistance, and then analyzed for DNA methylation and drug sensitivity after treatment with hydralazine.
Limitations
The study primarily focuses on a single cell line model, which may not fully represent all cancer types.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website